title: Low levels of lymphocyte MDR1 gene expression during early renal transplantation in patients treated with tacrolimus.
abstract: P-glycoprotein (P-gp) is a membrane efflux pump increasing the transport of drugs such as tacrolimus out of the cells. The aim of the study was to determine the kinetics of lymphocyte P-gp expression in patients treated with tacrolimus during the first 3 months following renal transplantation. Lymphocyte MDR1 gene expression was measured by semi-quantitative RT-PCR a few hours before transplantation, 3 weeks and 3 months after the graft. Lymphocyte MDR1 gene expression was low in all the 10 patients compared to 10 healthy volunteers: 0.30 +/- 0.07 arbitrary units (patients) vs. 1.74 +/- 0. 55 (healthy volunteers) (P = 0.0002). MDR1 gene expression decreased among the patients during the study: 0.28 +/- 0.12 (3 weeks later) and 0.12 +/- 0.09 (3 months later) (P = 0.006). We can conclude that lymphocyte MDR1 gene expression among patients before renal transplantation is low and remains low during the first 3 months following the graft.
authors.affiliation: Department of Pharmacology, St-Antoine Hospital, University Paris VI, 27, rue de Chaligny, Paris 75012, France. laurent.becquemont@chusa.jussieu.fr
authors.forename: L
authors.initials: L
authors.lastname: Becquemont
authors.forename: M
authors.initials: M
authors.lastname: Camus
authors.forename: F
authors.initials: F
authors.lastname: Kriaa
authors.forename: V
authors.initials: V
authors.lastname: Barbu
authors.forename: B
authors.initials: B
authors.lastname: Charpentier
authors.forename: P
authors.initials: P
authors.lastname: Jaillon
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis; D015870:Gene Expression / Q000187:drug effects*; D019450:Genes, MDR / Q000235:genetics*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation; D007700:Kinetics; D008214:Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D007166:Immunosuppressive Agents; D016559:Tacrolimus